Selected Publications

  1. Sodders MJ, Avila-Pacheco J, Okorie EC, Shen M, Kumari N, Marathi A, Lakhani M, Bullock K, Pierce K, Dennis C, Jenafavre S, Sarkar S, Scherzer CR, Clish C, Olsen AL. Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease. Biorxiv https://doi.org/10.1101/2024.05.15.594309
  2. Olsen AL, Locascio J, Tuncali I, Laroussi N, Abatzis E, Kamenskaya P, Kuras Y, Yi T, Videnovic A, Hayes MT, Ho GPH, Paulson J, Khurana V, Herrington TM, Hyman BT, Selkoe J, Growdown JH, Gomperts SN, Riise T, Schwarzschild MA, Hung AY, Wills A-M, Scherzer CR. Towards a phenome-wide view of Parkinson’s disease. medRxiv 2022.02.01.22270276; doi: https://doi.org/10.1101/2022.02.01.22270276
  3. Stephen CD, de Gusmao CM, Srinivasan SR, Olsen AL, Freua F, Kok F, Garcia Barbosa RM, Chen JY, Appleby BS, Prior T, Frosch MP, Schmahmann JD. Gerstmann-Straussler-Scheinker disease presenting as late onset slowly progressive spinocerebellar ataxia, and comparative case series with neuropathology. Movement Disorders Clinical Practice. 2024 11(4): 411-423. 
  4. Sodders MJ, Shen M, Olsen AL. Measuring constipation in a Drosophila model of Parkinson’s disease. Journal of Visualized Experiments. 2023 Sep 22(199).
  5. Natsuka N, Harrison D, Galetta KM, and Olsen AL. A case of an 85 year old woman with subacute onset of bilateral chorea. Annals of Clinical and Translational Neurology. 2024.
  6. Olsen AL, Clemens SG, Feany MB. Nicotine-Mediated Rescue of α-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila. Movement Disorders. 38(2):244-255. 2023.
  7. Ndayisaba A, Pitaro AT, Willett AS, Jones KA, Melo de Gusmao C, Olsen AL, Kim J, Rissanen E, Woods JK, Srinivasan SR, Nagy A, Nagy A, Mesidor M, Cicero S, Patel V, Oakley DH, Tuncali I, Hung AY, Wills A-M, Hayes MT, Macmore JP, Warren L, Bower PG, Langer CB, Kellerman LR, Humphreys CW, Glanz BI, Dielubanza EJ, Frosch MP, Freeman RL, Gibbons CH, Stefanova N, Chitnis T, Weiner HL, Scherzer CR, Scholz SW, Vuzman D, Cox LM, Wenning G, Schmahmann JD, Novak P, Young GS, Feany MB, Singhal T, Khurana V. Clinical trial-ready patient cohorts for multiple system atrophy: coupling biospecimen and iPSC banking to longitudinal deep-phenotyping. Cerebellum. 2022. 1-21. 
  8. Hagemann TL, Powers B, Lin N-H, Mohamed AF, Dague KL, Hannah SC, Bachmann G, Mazur C, Rigo F, Olsen AL, Feany MB, Perng M-D, Berman RF, Messing A. Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment. Science Translational Medicine. 2021. 13(620):eabg4711.
  9. Olsen AL and Feany MB. Parkinson’s disease risk genes act in glia to control neuronal α-synuclein toxicity. Neurobiology of Disease. 2021.159:105482. 
  10. Sarkar S, Bardai F, Olsen AL, Lohr KM, Feany MB. Oligomerization of Lrrk controls actin severing and alpha-synuclein neurotoxicity in vivo. Molecular Neurodegeneration. 2021. 16(1):33.
  11. Sarkar S, Olsen AL, Sygnecka K, Lohr K, Feany MB. α-synuclein impairs autophagosome maturation through abnormal actin stabilization. PLoS Genetics. 2021. 17(2):e1009359. 
  12. Parkhitko AA, Ramesh D, Wang L, Leshchiner D, Filine E, Binari R, Olsen AL, Asara JM, Cracan V, Rabinowitz JD, Brockmann A, Perrimon N. Downregulation of the tyrosine degradation pathway extends Drosophila lifespan. Elife. 2020. 15;9:e58053. 
  13. Sarkar S, Murphy MA, Dammer EB, Olsen AL, Bangaraiu S, Fraenkel E, Feany MB. Comparative proteomic analysis highlights metabolic dysfunction in PD. Nature Parkinson’s Disease. 2020. 6(1):40. 
  14. Argent L, Winter F, Prickett I, Carrasquero-Ordaz M, Olsen AL, Kramer H, Lancaster E, and Becker EBE. Caspr2 interacts with type 1 inositol 1,4,5-trisphosphate receptor in the developing cerebellum and regulates Purkinje cell morphology. Journal of biological chemistry. 2020. 285(36): 12716-12726.
  15. Sarkar S, Dammer EB, Malovic E, Olsen AL, Raza SA, Gao T, Xiao H, Oliver DL, Duong DM, Joers V, Seyfried NT, Huang M, Kukar T, Tansey MG, Kanthasamy A, Rangaraiu S. Molecular signatures of neuroinflammation induced by alpha-synuclein aggregates in microglial cells. Frontiers in Immunology. 2020. 11:33.
  16. Vaswani P and Olsen AL. Immunotherapy in progressive supranuclear palsy. Current Opinion in Neurology. 2020. 33(4):527-533. 
  17. Olsen AL and Feany MB. Glial alpha-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo. Glia. 2019. 67(10):1933-1957.
  18. Olsen AL and Feany MB. “PARP in Parkinson’s Disease: Clinical Implications of Basic Research.” NEJM. 2019. 380(5):492-494. 
  19. Olsen AL, Riise T, Scherzer CR. Discovering New Benefits from Old Drugs with Big Data – Promise for Parkinson’s Disease. JAMA Neurol. 2018. 75(8):917-920.
  20. Olsen AL and Herrington TM. “Movement Disorders.” Neurology Evidence: Practice Changing Studies. Philadelphia: Wolters Kluwer, 2017. 
  21. Olsen AL, Miller JJ, Bhattacharyya S, Voinescu PE, Klein JP. Cerebral perfusion abnormalities in stroke-like migraine attacks after radiation therapy (SMART) syndrome. Neurology. 2016. 86(8):787-9.